Changes in Waivers to Prescribe Buprenorphine for Opioid Use Disorder During COVID-19

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 12, 2022

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.5996?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051222

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: This case series examined the number of clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.

Authors: Joanne Spetz, Ph.D., of the University of California, San Francisco, is the corresponding author.

  

(doi:10.1001/jamanetworkopen.2022.5996)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.